Jacobs Levy Equity Management Inc. reduced its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 52.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,521 shares of the company's stock after selling 44,153 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.06% of Replimune Group worth $433,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Arizona PSPRS Trust bought a new position in Replimune Group in the 3rd quarter valued at about $834,000. Baker BROS. Advisors LP increased its stake in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock valued at $121,057,000 after acquiring an additional 1,000,000 shares during the period. Erste Asset Management GmbH bought a new stake in Replimune Group during the third quarter worth approximately $133,000. Braidwell LP lifted its position in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company's stock worth $33,656,000 after purchasing an additional 2,057,460 shares during the period. Finally, MetLife Investment Management LLC boosted its stake in Replimune Group by 21.5% during the 3rd quarter. MetLife Investment Management LLC now owns 35,134 shares of the company's stock valued at $385,000 after purchasing an additional 6,216 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company's stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.80% of the company's stock.
Replimune Group Stock Performance
NASDAQ REPL traded up $0.06 on Tuesday, hitting $12.70. 240,872 shares of the stock were exchanged, compared to its average volume of 1,053,254. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The company has a market capitalization of $868.93 million, a PE ratio of -4.14 and a beta of 1.26. The business's fifty day moving average is $12.14 and its 200 day moving average is $10.32. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.
Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on REPL. Roth Mkm started coverage on Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective for the company. Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, September 24th. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. Finally, BMO Capital Markets lifted their price target on Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research note on Friday, November 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $17.29.
Read Our Latest Report on Replimune Group
Replimune Group Profile
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Further Reading
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
